Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Renal Biopsy Clear all
Recruiting No phase listed Observational

Precision Medicine Approaches to Renal Osteodystrophy

NCT05880914
View directory record Official record
Conditions
Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions
miRNAseq analysis, Standard treatment for bone disorder
Procedure · Drug
Lead sponsor
Thomas Nickolas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Not listed No phase listed Observational

Prospective Assessment of Rejection in Kidney Transplant (PARK)

NCT05715853
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
QSant
Other
Lead sponsor
NephroSant
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 1:14 AM EDT
Completed No phase listed Observational

Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

NCT04855422
View directory record Official record
Conditions
Transplant; Complication, Rejection
Interventions
Allosure, AlloMap
Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 10, 2026, 1:14 AM EDT
Terminated No phase listed Observational

Study of OmniGraft in Simultaneous Pancreas Kidney Recipients

NCT06463873
View directory record Official record
Conditions
Kidney Transplant; Complications, Pancreas Disease
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 10, 2026, 1:14 AM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International (Pediatric) Peritoneal Biobank

NCT01893710
View directory record Official record
Conditions
Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
Interventions
biopsy sampling
Procedure
Lead sponsor
Heidelberg University
Other
Eligibility
1 Day to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Kansas City, Missouri • Narberth, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Not listed No phase listed Observational

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

NCT03630926
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hypertrophy, Bladder Stones, Kidney Stones
Interventions
NV-VPAC1 PCa Urine Diagnostic Test
Diagnostic Test
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 10, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 10, 2026, 1:14 AM EDT
Completed No phase listed Observational

Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants

NCT00001858
View directory record Official record
Conditions
Graft Rejection, Kidney Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 10, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores

NCT01496417
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Belatacept
Drug
Lead sponsor
University of Maryland
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 10, 2026, 1:14 AM EDT
Active, not recruiting Phase 4 Interventional

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121
View directory record Official record
Conditions
Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Active, not recruiting Early Phase 1 Interventional

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

NCT02210117
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Biopsy, Ipilimumab, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, Therapeutic Conventional Surgery
Biological · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting Phase 4 Interventional

Mechanism of SGLT2 Inhibition in the Kidney

NCT06291155
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
SGLT2 inhibitor
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Withdrawn Phase 2 Interventional

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

NCT07218692
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Sturlimogene Erparepvec, Tivozanib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Terminated Not applicable Interventional Results available

Shear Wave Elastography in Native Kidney Disease

NCT02830438
View directory record Official record
Conditions
Acute Kidney Disease, Chronic Kidney Disease
Interventions
Shear wave elastography
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 10, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

NCT00945009
View directory record Official record
Conditions
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
Interventions
Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
146
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 10, 2026, 1:14 AM EDT
Active, not recruiting No phase listed Observational

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

NCT03859388
View directory record Official record
Conditions
Rejection Chronic Renal, Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 10, 2026, 1:14 AM EDT
Active, not recruiting Not applicable Interventional

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NCT02735252
View directory record Official record
Conditions
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions
Systemic therapy, StrataNGS
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 10, 2026, 1:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

NCT03321656
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Envarsus XR
Drug
Lead sponsor
Roberto Gedaly
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 10, 2026, 1:14 AM EDT